NCT07257198 Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
| NCT ID | NCT07257198 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Montreal Heart Institute |
| Condition | NSTEMI - Non-ST Segment Elevation MI |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,570 participants |
| Start Date | 2026-03-03 |
| Primary Completion | 2030-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 2,570 participants in total. It began in 2026-03-03 with a primary completion date of 2030-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
Eligibility Criteria
Inclusion criteria: * Age ≥18 years; * Hospitalized for type 1 MI, according to the 4th Universal Definition of MI; * Coronary angiogram performed; * Planned for medical management alone, without revascularization; * Willingness to participate and to attend study visits; * Expected life expectancy ≥12 months. Exclusion criteria: * Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI; * Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel; * Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.); * Confirmed or suspected spontaneous coronary artery dissection; * Concomitant indication for chronic oral anticoagulant; * Concomitant non-coronary indication for dual antiplatelet therapy; * Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician; * Previous hospitalization for MI, PCI, or CABG within 12 months; * Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor; * Unsuitability for either randomization treatment, based on the judgement of the treating physician
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07257198 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NSTEMI - Non-ST Segment Elevation MI. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07257198 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 2,570 participants.
Is NCT07257198 currently recruiting?
Yes, NCT07257198 is actively recruiting participants. Contact the research team at guillaume.marquis.gravel@umontreal.ca for enrollment information.
Where is the NCT07257198 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT07257198 clinical trial?
NCT07257198 is sponsored by Montreal Heart Institute. The trial plans to enroll 2,570 participants.